Google
SCTX Stock Price & Analysis — Scribe Therapeutics Inc. Common Stock (Healthcare >> Biotechnology)
SCTX FAQ
What is SCTX's ROE?
Scribe Therapeutics Inc. Common Stock reports a Return on Equity (ROE) of 13.09%.
What is SCTX's dividend yield?
Scribe Therapeutics Inc. Common Stock offers a dividend yield of 0.00%.
What is SCTX's Quality Score?
Our AI rates SCTX's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy SCTX?
Our AI Timing Score for SCTX is 1 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does SCTX belong to?
Scribe Therapeutics Inc. Common Stock is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
SCTX AI Analysis Summary
Our AI summary for SCTX: Scribe Therapeutics Inc. Common Stock (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of 13.09%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 1/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 22.06
Price
1.23
(5.88%)
Day Change
|
|
|---|
SCTX, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 22.06 |
| PBV / Sector |
-2.12 / 44,022.72
|
| Earning Per Share | -1.36 |
| PE / Sector |
N/A / 19.17
|
| PEG or PE/Growth / Sector |
N/A / 1.24
|
| Average 1M Daily Value |
6.65 M
|
| Average 1W Daily Value |
3.26 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
54% |
| Return to Investors |
|
8% |
| Registration Details |
| Analyze Date | 2026-08-05 08:00:49 |
| Symbol | SCTX |
| Name | SCRIBE THERAPEUTICS INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 16.18 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 337.15 / 9,586.08 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1150 Marina Village Pkwy, Alameda, CA, United States, 94501
Phone: 510 626 8587
Website: https://www.scribetx.com
Employees: 89
Sector: Healthcare >> Biotechnology
Description: Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene and strongly reduce mRNA expression. It uses CRISPR-based platforms, such as ELXR, designed for precise, durable epigenetic silencing of genes without changing the underlying DNA sequence; and XE, designed to support specific and efficient gene editing. The company was incorporated in 2017 and is headquartered in Alameda, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap